---
agent_readiness:
  band: human-only
  dimensions:
    agent_card: false
    agent_skills: false
    agentic_access: false
    agentic_commerce: false
    auth_clarity: false
    consent_identity: false
    delegated_identity: false
    dry_run_mode: false
    dynamic_client_registration: false
    error_semantics: false
    event_surface_described: false
    idempotency: false
    mcp_server: false
    openapi_examples: false
    protected_resource_metadata: false
    rate_limit_signal: false
    reversibility_documented: false
    spec_presence: false
    well_known_catalog: false
  schema_version: 0.2
  score: 0.0
  scored_at: '2026-09-01'
api_count: 0
artifact_total: 1
common:
- group: auth
  title: ''
  type: DomainSecurity
  url: security/ratio-therapeutics-domain-security.yml
- group: company
  title: ''
  type: Website
  url: https://ratiotx.com/
- group: company
  title: ''
  type: Blog
  url: https://ratiotx.com/blog/
- group: company
  title: ''
  type: News
  url: https://ratiotx.com/news/
- group: operate
  title: ''
  type: Support
  url: https://ratiotx.com/contact-us/
- group: company
  title: ''
  type: Careers
  url: https://ratiotx.com/careers/
- group: build
  title: ''
  type: GitHubOrganization
  url: https://github.com/ratiotx
- group: company
  title: ''
  type: LinkedIn
  url: https://www.linkedin.com/company/ratio-therapeutics/
- group: agent
  title: ''
  type: LLMsTxt
  url: llms/ratio-therapeutics-llms.txt
coverage:
  checked: '2026-08-26'
  detail: Ratio Therapeutics is a clinical-stage radiopharmaceutical developer whose product is a drug pipeline ([Ac-225]RTX-2358 and the Trillium/Macropa platforms); ratiotx.com is a twenty-page WordPress.com marketing site where every contract-discovery path — /openapi.json, /swagger.json, /v1/openapi.json, /api-docs, /docs, /redoc, /graphql — returns the theme's 404, the company's GitHub organization at github.com/ratiotx has zero public repositories, and the only machine-readable surface is the CMS's default, undocumented /wp-json/ endpoint rather than a product API.
  evidence:
  - status: 200
    url: https://ratiotx.com/
  - status: 404
    url: https://ratiotx.com/openapi.json
  - status: 404
    url: https://ratiotx.com/swagger.json
  - status: 404
    url: https://ratiotx.com/api-docs
  - status: 404
    url: https://ratiotx.com/graphql
  - status: 404
    url: https://ratiotx.com/.well-known/api-catalog
  - status: 404
    url: https://ratiotx.com/.well-known/agent-card.json
  - status: 404
    url: https://ratiotx.com/.well-known/agent.json
  - status: 200
    url: https://ratiotx.com/llms.txt
  - status: 200
    url: https://ratiotx.com/wp-json
  - status: 200
    url: https://github.com/ratiotx
  reason: not-a-software-company
  state: none
created: '2026-08-26'
description: 'Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company headquartered at One Design Center Place in Boston, Massachusetts, developing next-generation precision radiopharmaceuticals for solid tumors. Founded in 2022 by Jack Hoppin, Ph.D. and John Babich, Ph.D., the company pairs two proprietary R&D platforms — Trillium, a tunable albumin-binding targeting scaffold that modulates pharmacokinetics, and Macropa, a bifunctional chelator built for the alpha emitter actinium-225 — to improve drug availability, tumor delivery and tumor loading. Its lead program, [Ac-225]RTX-2358, is a FAP-targeted radiotherapeutic in the ATLAS Phase 1/2 trial, alongside a next-generation GRPR program, mono- and bispecific radioligand therapies, and PET imaging assets. Ratio has licensing and collaboration agreements with Novartis, Merck, Bayer and Lantheus, isotope supply agreements with Nusano, TerraPower Isotopes and PanTera, and manufacturing partnerships with PharmaLogic and Eckert &
  Ziegler. It closed a $70 million Series C in July 2026, bringing total capital raised past $240 million. Ratio is a therapeutics developer rather than a software vendor: it publishes no developer program, no public API and no machine-readable API contract.'
image: https://i0.wp.com/ratiotx.com/wp-content/uploads/2023/03/ratiologo_clr_sansblock.jpg?fit=1325%2C588&ssl=1
layout: provider
modified: '2026-08-26'
name: Ratio Therapeutics
nav: Providers
network: true
overview: 'Ratio Therapeutics is profiled on the [APIs.io](https://apis.io/) network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Healthcare.


  Ratio Therapeutics'' developer surface includes engineering blog, product news, support, and 6 more developer resources.'
random_paper: 16
score:
  band: minimal
  composite: 5.8
  coverage:
    artifact_dirs: 4
    catalog_gap: 88.0
    catalog_max: 115.0
    note: Disclosure, not a penalty. catalog_gap is rubric points API Evangelist could add with no action by this provider; it is our backlog, not their gap, and it is NOT subtracted from the composite above.
  delta: 0.0
  facets:
    access_clarity: 0.0
    commercial_clarity: 0.0
    contract_governance: 0.0
    contract_quality: 0.0
    developer_ergonomics: 7.1
    discoverability: 57.4
    governance: 0.0
    operational_transparency: 2.6
  previous_composite: 5.8
  regulatory:
    applies: true
    matched_via: tags
    regime: Health
    regime_id: health
    score: 7.5
  schema_version: 0.18.0
  scored_at: '2026-09-01'
  trend: flat
security:
- kind: domain-security
  name: Ratio Therapeutics Domain Security
  slug: ratio-therapeutics-domain-security
  summary_line: TLSv1.3 · HSTS · DMARC
slug: ratio-therapeutics
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Healthcare
- Oncology
- Radiopharmaceuticals
- Drug Discovery
- Clinical Trials
- Precision Medicine
website: https://ratiotx.com/
---
